Takeda ends development of late-stage diabetes drug

|About: Takeda Pharmaceutical Co., ... (TKPHF)|By:, SA News Editor

"The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.

The drug was tied to liver damage.

The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.

Shares fell 5%+ in Tokyo on the news.